Introduction
In the absence of an effective clinical treatment for age-related neuro-degenerative disorder, research has focused on the identification of potential risk factors in order to delay cognitive decline and prolong autonomy. Reversible drug-induced cognitive impairment has been described in clinical studies of patients with cognitive impairment or neuropsychiatric disorder. They have generally focused on acute or short-term administration of anticholinergic medication and delirium. Few community studies have however, been undertaken in spite of 1 the relatively high intake of over-the counter and prescription drugs consumed by the elderly. Several cross-sectional studies in elderly 2
persons have demonstrated a link between anticholinergic medication and global cognitive functioning, psychomotor speed, , visual 3 -6 7 8 and declarative memory, and implicit learning. The causal relationship between long-term use of anticholinergics and sub-clinical 4 7 cognitive decline thus remains unclear due to the scarcity of longitudinal population studies. In a retrospective study of 592 older adults, Bottiggi et al. observed an accelerated decline over a six-year period of psychomotor speed and executive functioning in anticholinergic users. In a sample of 372 elderly subjects, we have previously reported a significant association between continuous anticholinergic useArch Intern Med . Author manuscript Page / 2 14 over one year and poorer performance on specific cognitive domains.10 Most importantly, anticholinergic drug use was observed to be a strong predictor of mild cognitive impairment (MCI) although risk of subsequent dementia could not be estimated due to small numbers. Very recently, in a cohort of 544 community-dwelling older men with hypertension, cumulative anticholinergic exposure was shown to be associated with poor performance on verbal memory over 2 years.11
Surprisingly, previous studies have not examined genetic vulnerability although two small randomized controlled trials (RCTs) suggested increased cognitive sensitivity in subjects with an apolipoprotein E (ApoE) 4 allele shortly after acute anticholinergic ε administration. , Gender differences have also not been considered although different risk profiles for both MCI and progression to 12 13 dementia have been reported between men and women. Finally, there is some evidence that short-term estrogen pretreatment may 14 attenuate anticholinergic-induced cholinergic dysfunction , suggesting possible protective effects of hormone replacement therapy 15 16 (HRT). This hypothesis has yet to be tested.
Thus, while there is accumulating evidence to suggest that anticholinergics may increase risk of cognitive decline and dementia, this hypothesis remains to be tested within a large prospective study able to take into account multiple independent and interactive causes of cognitive decline. The possible reversible effect on cognitive functioning of stopping anticholinergic treatment has also never been evaluated. The aim of the present study was to examine the relationship over time between anticholinergic use and cognitive decline and onset of dementia in community-dwelling elderly taking into account gender and genetic vulnerability.
Subjects and Methods

Study population
Subjects were recruited as part of a multi-site cohort study of community-dwelling persons aged 65 years and over from the electoral rolls of three French cities between 1999 and 2001.
The study protocol was approved by the Ethical Committee of the 17 University-Hospital of Bic tre (France) and written informed consent was obtained from each participant. The subjects were followed up ê every 2 years for 4 years. Of the 9077 dementia-free participants included in the cohort, 363 died, 631 were lost to follow-up, and 1171 did not have repeated cognitive testing, or had missing data for at least one base-line adjustment variable. The present analyses were conducted on 6912 subjects. Of these, 914 subjects (13.2 ) had only one follow-up examination. The average follow-up (SD) was 3.5 % years (0.6). Subjects not included in the present analysis were more frequently women, older, with lower education level, more frequently using anticholinergics, and with lower base-line cognitive scores (data not shown). There were 59.7 of women in the sample. The mean % age (SD) was 73.6 (5.3) for men and 73.8 (5.2) for women.
Cognitive outcome measures
A battery of cognitive tests assessed different areas of cognitive functioning. Isaacs Set Test provided a measure of verbal fluency or 18 semantic access which is sensitive to changes in both frontal and temporal areas. Participants were asked to generate as many words as possible within a given semantic category (animals, colors, fruits and cities) in a limited time. Fluency was assessed as the total score corresponding to the sum of the number of words generated in each category within 30 seconds ( Isaacs total retrieval ), as well as the " " number of words reported for the first ( early retrieval ) and the second 15-second interval ( late retrieval ). Benton s Visual Retention Test
(BVRT) assessed visual memory; psychomotor speed and executive function were assessed with the Trail Making Tests A and B 19
respectively (TMA and TMB) and the Mini Mental State Examination (MMSE) was used as a global measure of cognitive function. 20 21 All of the cognitive tests were administered at base-line, and during wave 1 and 2 of the follow-up, except the TMT A and B, which were not given in wave 1. Consequently, the analysis based on these tasks involves only 5716 participants. Cognitive decline was defined as being in the lowest quintile of the difference between base-line score and either follow-up visit (after 2 or 4 years) except for TMT for which the highest quintile of the difference was considered.22
Diagnosis of dementia
A preliminary diagnosis and classification of dementia at each follow-up examination was made by the 3C study local clinical investigators according to DSM-IV revised criteria, and validated by a national panel of neurologists independently of the 3C 23 investigators. The date of onset of dementia was the date of the follow-up interview when dementia was diagnosed.
Anticholinergic drug use
An inventory of all drugs (prescription and over-the-counter drugs) used during the preceding month was included in a standardized interview. Medical prescriptions and, where feasible, the medications themselves were checked by the interviewer. Reported medicines were coded according to the World Health Organization s Anatomical Therapeutic Chemical (ATC) Classification. 
Socio-demographic and clinical variables
Page / 3 14 The standardized interview included questions on demographic characteristics, education level, marital status (married/widowed/single or divorced), mobility, height, and weight. Information was obtained on alcohol consumption, tobacco use, caffeine consumption, and HRT for women. History of stroke, angina pectoris, myocardial infarction and cardio-vascular surgery was established according to standardized questions with additional information where necessary from general practitioners. Recent asthma crisis, hypertension, hypercholesterolemia and diabetes were also recorded. Depressive symptomatology was assessed by the Center for Epidemiological Studies-Depression Scale (CES-D) with a 16 cut-off point. Fasting blood samples were taken for cholesterol levels and ApoE 25 genotyping as described previously.22
Statistical analyses
We used univariate and multivariate logistic regression analyses to determine if base-line consumption of anticholinergic drugs was associated with odds of cognitive decline. Men and women were examined in separate analyses as they differed in both anticholinergic drug use and profiles of cognitive ability. The Chi2 test was used to identify gender-related differences. After gender stratification, univariate odds ratios were adjusted for centre, age, educational level, and base-line cognitive performance ( ). Multivariate model 0 adjusted logistic regression included covariates that were associated with cognitive decline (p<0.15).
was adjusted for centre, age, Model 1 education, base-line cognitive performance, body mass index (BMI), alcohol, tobacco, and caffeine intake, mobility, hypercholesterolemia, ApoE, diabetes, asthma, and HRT for women. Compared to model 1, was further adjusted for pathologies associated with model 2 anticholinergic drug use in order to take into account a possible prescription bias, depression, ischemic pathologies, Parkinson s e.g. ' disease, and hypertension. For analyses taking into account number of anticholinergic medications we used model 2 where gender was an adjustment variable (instead of stratifying by sex) due to low numbers in several categories.
A Cox model with delayed entry was used in the analysis of dementia incidence taking age as the basic time scale and birth as the time origin. This analysis was undertaken on 7123 subjects without missing data for base-line adjustment variables but with possibly missing 26 repeated cognitive testing. The analyses were not stratified by sex to allow full adjustment in spite of relatively small numbers of incident cases. The full model was adjusted for sex, centre, education, BMI, alcohol, tobacco and caffeine intake, mobility, hypercholesterolemia, ApoE, diabetes, asthma, depression, ischemic pathologies, Parkinson s disease and hypertension. Analyses were carried out using SAS ' software (version 9.1).
Results
Population characteristics
Within this elderly community-dwelling population, 520 of the 6912 subjects (7.5 ) were taking anticholinergic drugs at base-line, of Table 1 = with diabetes (p 0.007), ischemic pathologies (p 0.02) or Parkinson s disease (p 0.0001) were more frequent anticholinergic drug users.
Associations between anticholinergics and cognitive decline over 4-year follow-up
In the longitudinal logistic regression analyses, decline in cognitive performance was defined as a decrease from base-line of at least 6 points on the Isaacs total score or at least two points on the Benton test and the MMSE (lowest quintiles). For TMT, cognitive decline was defined as an increase from base-line of at least 16 (TMTA) or 35 seconds (TMTB) ( ). In women, univariate logistic regression Table 2 total score in women. This effect appeared related to the early retrieval phase (OR 1.27, CI 0.99 1.62, p 0.06) whereas no significant = = -= association was found for the late retrieval (data not shown). In men, the OR was 1.63 (CI 1.08 2.47, p 0.02) for decline in the Benton
On the other hand, the association with decline in the TMTB in men was no more significant in model 2 (p 0.14), as well as for Compared to women who had never reported anticholinergic drugs, women of the continuous group were at higher risk of cognitive 
The same pattern was observed for men in the continuous group in relation to decline in the Benton test (OR 1.94, CI 1.15 Table 3 " " = = -3.27, p 0.01) and the TMTB (OR 1.94, CI 1.06 3.58, p 0.03). On the other hand, the risk was not significantly modified for subjects
having discontinued anticholinergic drugs.
Associations between base-line anticholinergic drug use and 4-year incidence of dementia
Of the 7123 subjects included in the analysis concerning dementia outcome, there were 221 newly diagnosed cases during follow-up, of whom 143 had Alzheimer s disease. In the sub-sample from which intermittent users were excluded, a multi-adjusted delayed-entry Cox 
Discussion
In this large prospective study, 7.5 of these community-dwelling elderly persons reported taking anticholinergics. Our results % indicate an increased risk in cognitive decline and dementia which remained significant after adjustment for the other multiple possible co-determinants of cognitive decline. It should be mentioned that similar results were obtained in the unadjusted model (model 1) and in the model that adjusted for the pathologies associated with anticholinergic treatment (model 2). This suggests that the anticholinergic drugs themselves rather than the underlying burden of illness is the likely cause of the cognitive decline. Further supporting a causative effect of the anticholinergic medications we found that the cognitive decline appeared reversible after anticholinergic treatment was discontinued.
This could at least partly account for the reversible dementia observed in some patients with MCI. , 27 28 Association between anticholinergics and cognitive decline and gender specificity
Chronic anticholinergic use was specifically associated with a significant decline in visual memory or executive function in men and in verbal retrieval in women. Our data indicate a specific effect on early retrieval but not late retrieval which could suggest an effect on speed of information processing rather than on search processes. For women, an effect on a global cognitive measure targeting more 29
severe decline was also observed. Some of these alterations in cognitive performances have already been observed in previous cross-sectional studies as well as in retrospective, and prospective , longitudinal studies although possible gender differences 3 -8 9 10 11
were not previously considered.
In women, we observed an age-by-anticholinergic intake interaction effect, the oldest women being at higher risk of global cognitive decline (p 0.002). The elderly are known to be more sensitive than the young to cognitive toxicity associated with acute anticholinergic = drug administration, which has been ascribed to decreased central cholinergic function. Our data suggest a significant age-related 30 -33 vulnerability to anticholinergics in elderly women whereas no significant interaction was found in men, but the results could have been limited due to the lower number of men in our sample.
Endocrinological factors can modulate cognitive function in elderly women.
Dumas et al. reported that short-term estrogen 34 pretreatment could attenuate anticholinergic-induced cognitive impairments in two small RCTs with 15 and 22 postmenopausal women. 15 ,
In the present study we found an interactive effect on cognitive decline in early retrieval between anticholinergic intake and HRT use 16 which suggests that estrogen status in postmenopausal women may be important for cholinergic system integrity. 5 14 We also observed a significant interaction between anticholinergic intake and ApoE; women taking anticholinergics and carrying 4 ε allele being at 2-fold higher risk of global cognitive decline than non-carriers. In two RCTs in which 24 cognitively intact elderly subjects were administered a single dose of the muscarinic antagonist, trihexyphenidyl, the 4 allele positive but not the 4 negative participants ε ε demonstrated significant impairment in total and delayed recall 5h after treatment. , Gender differences were not considered in these 12 13 small RCTs although a greater deleterious effect of ApoE4 on gross hippocampal pathology and memory performance has been reported in women than in men with MCI. Our data suggest that the 4 allele could play a significant role in increasing long-term cognitive 35 ε vulnerability to chronic anticholinergic burden in elderly population and that this effect could be particularly evident in postmenopausal women. Estrogen has been reported to be associated with less cognitive decline among 4-negative women but not 4-positive women.
ε ε
36
Both characteristics ( 4-negative women taking HRT) may thus contribute to a higher protective effect against anticholinergic ε neurotoxicity.
Dementia
We observed a significant association between anticholinergic use at base-line and the risk of developing dementia at 4-year follow-up. In a previous study conducted on an independent cohort we found anticholinergic report to be a risk factor for MCI, but numbers were insufficient to determine risk of dementia incidence. In the present study, we observed that chronic anticholinergic users 10
were at higher risk of incident dementia compared to non users, or persons having discontinued intake at the beginning of the follow-up.
While this finding has not been previously reported, this agrees with the study by Perry et al. on autopsied Parkinson s disease patients ' treated with anticholinergics; Alzheimer-type pathology being observed in patients who had been treated for more than two years compared to short-term anticholinergic treated or untreated cases.37
Several mechanisms may be postulated to explain how anticholinergic drug use may increase dementia risk. One possibility is neurotransmitter down-regulation. There is also the possibility of misdiagnosis of early dementia when in fact the patients are suffering 38 from cognitive decline secondary to anticholinergic drug use.
Limitations
The data concerning some of the covariates were self-reported with eventual subsequent recall bias. Bias could also have been introduced through the exclusion of participants, those lost to follow-up being more likely to have dementia, women, older, with lower education level and base-line cognitive scores and more frequent anticholinergic users. The higher dropout rate in this group may also limit the generalizability of our results. Furthermore, there are several methods for estimating anticholinergic burden. All of them have merits and limitations, with no ideal evidence-based approach . We did not use or measurement of anticholinergic activity 39 in vitro ex vivo (using radiolabeled muscarinic agonist) but a method based on anticholinergic drug lists which is the only clinically useful method for routine clinical practice. We did not consider treatment compliance, which may have caused classification bias. Since we did not have data on precise duration of medication use, we could not definitively address the question of whether the effects are essentially transient or whether prolonged use could precipitate non-reversible dementia. Besides, we cannot exclude that there are other unknown factors including subclinical disease (in addition to that detectable through the analysis of lipids, glycemia and hypertension), which may confound the association between anticholinergic report and cognitive decline or dementia. Finally, since multiple analyses have been performed we cannot exclude that some observed associations were due to a chance finding.
Strengths
The data used in the analysis comes from a large multicentre population-based prospective study of people aged 65 years and over. Anticholinergic use was verified by examining the prescriptions and medications themselves, thus minimizing exposure misclassification.
We have already reported within the same cohort that interviews and reimbursement data could estimate current exposure to chronically used drugs (including anticholinergic medication) similarly, with the advantage that self-medication being better described with interviews. Finally, we have taken into account a wide range of competing causes of cognitive dysfunction in the elderly, by controlling 40
for socio-demographic, genetic, health and lifestyle covariates and thus limiting any potential confounding. Despite this, there were only minor changes between the unadjusted and adjusted analysis, notably after adjusting for pathologies associated with anticholinergic indication suggesting independence of associations.
Conclusion
Findings from this study suggest that the use of medication with anticholinergic effects was associated with an increased risk of cognitive dysfunction and dementia in elderly persons. Discontinuing anticholinergic treatment was associated with a decreased risk.
Medical practitioners should monitor current anticholinergic drug use in elderly patients and seek pharmacological alternatives before considering administration of neuroprotective medications to persons with MCI, thus escalating a prescription cascade involving
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